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Abstract The commonest autosomal deletion, 22q11.2 dele-
tion syndrome (22q11DS) is a multisystem disorder varying
greatly in severity and age of identification between affected
individuals. Holistic care is best served by a multidisciplinary
team, with an anticipatory approach. Priorities tend to
change with age, from feeding difficulties, infections
and surgery of congenital abnormalities particularly of
the heart and velopharynx in infancy and early childhood to
longer-term communication, learning, behavioural and
mental health difficulties best served by evaluation at
intervals to consider and initiate management. Regular
monitoring of growth, endocrine status, haematological
and immune function to enable early intervention helps
in maintaining health. Conclusion: Guidelines to best
practice management of 22q11DS based on a literature
review and consensus have been developed by a national
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group of professionals with consideration of the limitations of
available medical and educational resources.
Keywords 22q11 deletion syndrome . Guidelines . Di
George . Velocardiofacial . Congenital abnormalities .
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Abbreviations
22q11DS 22q11.2 deletion syndrome
SMCP Submucous cleft palate
VPD Velopharyngeal disproportion
Introduction
The effective and efficient use of resources in conditions with
multiple disabilities is one of today’s major challenges. A
United Kingdom (UK) government-led initiative, the National
Service Framework for Children [11], aims for the child with
complex needs to receive co-ordinated high quality child and
family centred care. Needs are to be assessed through the use
of evidence-based guidelines and protocols which are regu-
larly updated, and their implementation subject to local audit.
The present international economic climate is affecting many
national health budgets adversely [14, 64]. It is therefore
timely to consider the minimum set of safe medical standards
and screening procedures for 22q11.2 deletion syndrome
(22q11DS) consistent with best practice recommended inter-
nationally [5, 19]. In addition to identifying established prob-
lems such standards should also anticipate their onset when-
ever possible. This has the benefit of potentially avoiding or
reducing complications likely to impair well-being and addi-
tional burdens on health and community resources.
The 22q11DS population prevalence is reported to be one
in 4,000 to one in 6,000 [6]. It equates annually to between
900 and 1,350 affected individuals from among the 5.4 mil-
lion births each year in the European Union. With present-day
treatment, survival beyond infancy is 90–95 % [32, 50],
although life span may be reduced in some as adults [4]. As
they become adults the less severely affected may become
parents, their children adding to the burden of care for the
community. The number of affected individuals of all ages in
the UK and Ireland, population 66 million, is probably
10,000–15,000, assuming survival to middle age. It is likely
that only the more severely affected children and a small
proportion of adults are currently correctly identified and
receiving appropriate support from social, educational and
health services [33].
The 22q11.2 deletion is a 1.5- to 3-megabase deletion on
the long (q) arm of chromosome 22. The deletion contains
TBX1, the major candidate gene, and other genes, controlling
the third and fourth pharyngeal arches, brain and skeletal
development. Haploinsufficiency results in the principal
syndrome phenotype. No correlation between the size or site
of the deletionwith phenotype has yet been found [22, 29, 39].
The deletion occurs spontaneously in 85–90 % of patients or
is inherited from either parent in an autosomal dominant
fashion. An unaffected parent may carry the deletion in their
egg or sperm (germline mosaicism); their recurrence risk is
1% [51]. The syndrome is a multisystem disorder with several
major features, and many less severe abnormalities which aid
detection [59], in conjunction with typical facial dysmorphia
(Fig. 1) which collectively are not always appreciated by
clinicians. The multitude of combinations can cause diagnos-
tic confusion, a legacy of which has been the nomenclature
applied to apparently different syndromes (Di George,
velocardiofacial, conotruncal) now known to be usually due
to the 22q11.2 deletion [67]. Those with the phenotype but
without the deletion comprise up to 20 % and are usually
referred to as Di George syndrome; their management follows
the same guidelines. Rates of detection increase where spe-
cialists are familiar with the condition [46]. Diagnosis in 95 %
of subjects with the deletion has been by fluorescent in situ
hybridisation (FISH), and is being superseded bymethods that
also reveal the 5 % of atypical deletions which FISH fails to
identify. They include array comparative genome
hybridisation (aCGH), genome wide microarrays and multi-
plex ligation-dependent probe amplification (MPLA) [40].
The major conditions occurring in approximately 70 % or
more are congenital heart disease, immune deficiency, palate
defects affecting feeding and speech, and learning difficulties
[28]. Those found in 25–50% include feeding disorders, early
growth faltering, gut dysmotility, psychiatric, behavioural and
neurological conditions, structural (renal, skeletal, brain, gas-
trointestinal, eye and dental) abnormalities, hearing impair-
ment, hypocalcaemia, haematological and autoimmune disor-
ders [32, 34, 50, 61].
Method
Guidelines for the management of 22q11DS evolved from a
consensus document initiated by the parent-led charity Max
Fig. 1 Child with 22q11.2 deletion syndrome
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Appeal [31], to promote good practice in the UK across
publicly funded community and health services. The consen-
sus participants were parents, clinicians and therapists with
extensive experience in managing the condition.
The SIGN [52] systematic literature review system’s
highest level of evidence is 1++ through eight grades to the
lowest level 4; it was applied to the 22q11DS literature found
in PubMed and via the National Health System Athens search
engine up to December 2012. It comprised some case control
studies, many case series and numerous case reports. Those
reported here by level in {} brackets ranged from {2+} to {4}.
The highest grade of recommendation is {A} though {D}.
Those relating to 22q11DS generally comprised grade D {D}
defined as evidence level {3} or {4} or extrapolated evidence
from studies rated as {2+}, and Good Practice {GP} recom-
mendations based on the clinical experience of the guideline
development group. By extrapolation, conventional treatment
appears as efficacious in 22q11DS as for those with similar
but unrelated conditions, with a significant exception being
velopharyngeal disproportion (VPD), and informed the rec-
ommendations accordingly.
Age appropriate investigations and assessments were eval-
uated from the literature, the prevalence of 22q11DS associ-
ated disorders, and the need for information to guide manage-
ment and advice giving [28, 29, 32, 34, 50, 61].
Presentations
By age
Fetal anomaly screening may result in identifying that the
foetus is affected, and in some instances one of the parents,
more likely the mother, is also affected. Careful multidisci-
plinary assessment of the pregnancy is required {C}.
The individual with 22q11DS is likely to present changing
clinical and psychosocial priorities from birth to maturity
(Fig. 2). Early care is dominated by organ malformations
requiring surgery, feeding support, and treating infections; as
childhood progresses, neurodevelopmental, behavioural and
educational priorities require attention; in adolescence, scoli-
osis monitoring with possibly surgical intervention, and psy-
chosocial support; in adults socioeconomic, general medical
and psychiatric support.
Severity, even between affected members of the same
family, is highly variable {3}.
By system
Gestalt
Facial dysmorphia (Fig. 1) are subtle especially in infancy,
and also appear less marked in adults. They include long
narrow face, almond shaped eyes, a bulbous nose (becoming
evident with age), small mouth, overfolded ear helix, asym-
metry of facial movement {3}, and occasionally skull asym-
metry due to craniosynostosis {4}.
Cardiac disorders
Cardiac malformation prevalence varies from 80% to 92% of
those presenting in infancy [43, 46] to 40–50 % presenting in
childhood [29, 35], and predominantly comprise conotruncal
anomalies. They may appear shortly after birth with cyanosis
due to reduced blood flow to the pulmonary circulation by
right ventricular outflow obstruction as in Fallot’s tetralogy
and pulmonary atresia, (with or without multiple
aortopulmonary collateral arteries [MACPA]), or with cardio-
vascular collapse due to systemic outflow obstruction from
aortic arch narrowing or interrupted aortic arch (most
COMMUNICATION, PSYCHOLOGY SERVICES
Fig. 2 Need of specialties by age
of 22q11 DS children
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frequently type B) [32, 50]. The obverse, an increase in blood
f low due to la rge shun t s such as VSD (of ten
perimembranous), and truncus arteriosus, may present with
heart failure within a few days or weeks. An aberrant subcla-
vian artery may present with feeding difficulties or respiratory
symptoms. Alternatively, conditions such as right sided aortic
arch or valve defects may be identified only incidentally after
initial referral for concern about other issues, for example,
about speech or developmental delay.
Management: a cardiology opinion, electrocardiogram and
echocardiogram are mandated at the time of diagnosis of the
deletion if not performed before {C}. Treatment is
individualised according to the underlying lesion. If the first
assessment is normal no further routine review is required.
Hypocalcaemia
Hypocalcaemia is usually due to hypoparathyroidism, vari-
able in duration (from transient in neonates, to resolving in
months to years) and is rarely lifelong. Point prevalence of
hypocalcaemia outside the neonatal period was 30 % of 27
subjects of all ages [58], with a lifetime prevalence of 50 %
[3]. Hypocalcaemia was detected in 40 % of those with
seizures [19, 50]. It presents clinically as jitteriness, seizures
which may need to be further investigated as prevalence
of epilepsy is increased, or stridor that needs to be
differentiated from laryngeal web which is also more
prevalent in 22q11DS. Symptomatic or biochemical
hypocalcaemia may also be precipitated by the stress
of surgery, and by increased needs during puberty or
pregnancy. Dentition may be prone to caries {4}.
Management: monitor by checking the (ionised) calcium
level 3 monthly in infancy and annually thereafter {D}. Low
calcium and raised phosphate should initiate a check for an
inappropriately low parathyroid hormone and normal vitamin
D level.
Calcium supplements and various formulations of vitamin
D and analogues are generally effective treatments {C} but
careful monitoring is required in patients with associated
structural renal anomalies such as unilateral renal agenesis or
dysplastic kidney. Daily Vitamin D is advised for all ages
{GP}. The dose should be the recommended daily allowance,
or as therapeutically indicated {B}.
Immune system disorders
(a) Immune disorders affect the majority of patients, are
commonly mild and manifest mainly as reduced T cell num-
bers and function. The thymus may be absent. Reduced levels
of IgA and IgM in older children occur more frequently than
the general population. The T-cell deficiency undergoes spon-
taneous improvement in most individuals, usually by 2 years
of age.
Almost all patients have a greater than average tendency to
infections, particularly of the respiratory tract, even when
laboratory tests of immune function appear normal [16].
Pneumonia occurs in 10 %, mainly in infancy and preschool.
Recurrent upper respiratory infections, especially otitis media,
are more frequent and persistent; concomitant VPD may
contribute. Infectious episodes reduce in frequency with age.
Early feeding problems may result in nutritional anaemia;
autoimmune (Evans) anaemia and significant thrombocytope-
nia may occur at any age.
Monitor: baseline immunology testing (see Table 1) {C},
and annual full blood count {GP}.
Management: only 1 % have no T cells, requiring urgent
referral to a supra-regional centre for assessment and, if avail-
able, thymus transplant {C}. Antifungal, antiviral and anti-
pneumocystis prophylaxis and immunoglobulin replacement
Table 1 Recommendations for investigation, management and referral
Investigations at diagnosis
• At diagnosis
a. Full blood count including differential white cell count, lymphocyte
phenotyping, immunoglobulinsG, A,M. Lymphocyte proliferation
testing if readily available and T cell count low; post immunisation
tetanus or Hib antibodies {B}.
b. Serum calcium, thyroid function {B}.
c. Cardiological examination, echocardiogram and
electrocardiogram {B}.
d. Parental 22q11 status, and siblings if a parent is affected {B}.
e. Renal ultrasound looking for single kidney, cysts, dilated
collecting system {B}.
Essential initial actions
• Irradiated cytomegalovirus negative blood products if immune
status is unknown or severely affected {C}. Urgent specialist
referral if T lymphocytes appear virtually absent or very low.
• Vaccination: Primary vaccination should be given promptly, including
Mumps Measles and Rubella (MMR) {D} even if the CD4 count is
low {D}. Chickenpox vaccination is not given with a CD4 count
below 200/ml, as in Human Immunodeficiency Virus {GP}. Avoid
BCG, and consult an immunologist if circumstances require {GP}.
Specific medical examinations
• Genetics: At diagnosis, and repeated when the family and emerging
adult have a need {GP}.
• Special senses: hearing test and eye examination at diagnosis {C}.
Orthoptic and refractive examination at 3 years, and ophthalmic
examination as clinically indicated.
• Musculoskeletal system:
Scoliosis examination at diagnosis and between 10 and 12 years,
in the earlier part of the adolescent growth spurt {D}.
Locomotor system examination for limb pain, stiffness, swelling;
arthritis can present as delayed development in young children.
Depending on clinical findings appropriate investigations include
inflammatory markers, autoimmune serology, and ultrasound {GP}.
• Monitor height and weight frequently up to 2 years old, annually
thereafter. Slowing of growth warrants full assessment, including
screening for thyroid and growth hormone deficiency {D}.
• Autoimmune disorders if clinically indicated: autoantibodies
including direct antiglobulin test and thyroid antibodies {D}.
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therapy should be commenced {B, C}. Cytomegalovirus neg-
ative and irradiated blood products are not routinely adminis-
tered to infants undergoing cardiac surgery in the UK unless
an immune deficient state is suspected {C}.
In selected individuals, who present with recurrent upper
respiratory tract infection, even with ‘normal’ immune func-
tion tests, antibiotic prophylaxis in winter may be beneficial in
reducing infections and supporting school attendance {GP}.
(b) Autoimmune phenomena. Auto-immune conditions are
found in up to a third, and symptomatic in a fifth as juvenile
chronic arthritis (JIA), autoimmune thrombocytopenia,
haemolytic anaemia, Raynaud’s phenomena, and autoimmune
thyroid disease [9, 16, 27]. Low IgA is a feature in JIA in
22q11DS [9].
Monitor: clinical review and annual full blood count {D}.
Feeding and growth
(a) Feeding problems. Feeding problems in the first year are
common [50], affecting up to 68 % [29]. Cleft palate and
submucous cleft palate (SMCP) are found in 14 % [50]. If
feeding difficulties are encountered in the neonatal period, the
possibility of an overt or a SMCPmust be investigated and the
child referred to the local specialist cleft lip and palate service
who will advise on feeding and whether a modified cleft
feeding bottle may be appropriate.
Gastro-oesophageal reflux is common and dysphagia
(10 %) may cause recurrent silent aspiration and pneumonia.
Management includes thickeners, anti-reflux and propul-
sive medication {C}, and nasogastric feeding. Gastrostomy is
indicated if the airway is significantly compromised, as dem-
onstrated onX-ray barium contrast swallow or associated with
recurrent aspiration pneumonia {C}.
(b) Growth disorders. Weight faltering frequently occurs
{2+}. Although 40 % fall below the 3rd centile in height and
weight in the first year [23, 50], this does not correlate with
cardiac or feeding disorders. Catch-up in height takes
place by late childhood ultimately to a little below
average by adult life, with a prevalence of obesity
observed in French children [47] to be similar to the
surrounding general population {3}. Hypothyroidism,
hyperthyroidism and growth hormone deficiency are
increased in frequency {4}.
Management: see Table 1.
Genitourinary tract
Renal abnormalities are found in 7–36 %, comprising absent,
dysplastic or multicystic kidneys, obstructive abnormalities,
vesicoureteric reflux, and nephrocalcinosis secondary to cal-
cium and vitamin D supplementation [29, 32, 50]. Genital
anomalies including undescended testes and hypospadias are
increased.
Management: ultrasound examination generally deter-
mines the pathway for management {B}.
Musculoskeletal system disorders
(a) Hypotonia and ligamentous laxity are very common, as is a
disinclination to walk even short distances, with frequent
complaint of leg pains which are usually symmetric;
asymmetry suggests other pathologies {3}. The pain
may cause waking at night, contributing to daytime
inattention. Unsteady gait, incoordination and clumsy
hand skills are common. Patella dislocation and rheu-
matoid arthritis are increased [9] compared with the
general population {4}.
Management: assess gait, limb pain, joint swelling, early
morning stiffness, or delayed motor development with these
comorbidities in mind. Specialist referral to a paediatric rheu-
matologist and specialist physiotherapist may be indicated
{GP}.
(b) Cervical spine examination. Radiological abnor-
malities of the cervical spine region are very common
[48]. As in Down’s syndrome and other genetic syn-
dromes [36] evidence of cord compression is rare {3},
and evidence is lacking that cervical X-rays have vali-
dated predictive value for subsequent acute dislocation/
subluxation at the atlantoaxial joint [30, 65].
Management: seek advice expeditiously in the pres-
ence of any physical or neurological symptoms or signs
of cord compression. Anaesthetists should be alerted to
the possibility of cervical spine injury whilst manipulat-
ing the head and neck in the unconscious 22q11DS
patient. No limitations on sports are imposed, subject
to suitable supervision and support {GP}.
(c) Scoliosis. The prevalence of scoliosis in 22q11DS is 9–
24 % [8, 29, 46, 61], 3–8 times that of the general population.
Of those with scoliosis 6 % require surgical management [8].
Most frequently the radiological appearance is of Adolescent
Idiopathic Scoliosis. Hemivertebrae and other skeletal anom-
alies also occur.
Management: clinical examination of the spine at diagnosis
and ages 10 to12 years is recommended {D}.
Speech and communication disorders
Articulation and communication problems occur in two-
thirds, characterised by hypernasal articulation due to
VPD [32], cleft palate and SMCP. Expressive speech
delay may initially be greater than performance based
abilities, yet subsequently overtake the latter [54]. This
phenomenon is considered to be syndrome specific [3].
Management: assessment and intervention through
speech and language therapists, with early referral to
a cleft surgery centre when VPD is suspected.
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Palatopharyngeal surgery generally improves compre-
hensibility, but residual VPD may remain [37, 55].
Hearing
Deafness is due to otitis media and secretory otitis
media in 75 % {3}; up to 15 % [12, 50] have sensorineural
deafness {3}. Eustachian tube dysfunction associated with
cleft palate or SMCP and immune deficiency, contributes to
conductive loss.
Management: universal hearing testing occurs at birth in
many economically developed countries, and is repeated at 4
to 5 years {B}. Additional examinations are as indicated
clinically, in the presence of delayed speech and language
development {C}.
Intelligence and educational assessment
Intelligence scores are shifted lower. The mean IQ is in
the low 70s; 30 % lie in the low normal IQ range
between 80 and 100 [46, 56, 68]. Less than 20 % have
moderate to severe learning difficulties. By school age
verbal ability usually advances to be similar to or better
than performance-related ability. Memory, and hence
rote learning, is usually a strength. Ability to grasp
abstract concepts, especially mathematics, is weak. Attention
difficulties, visual spatial difficulties, and impaired executive
function with similarities to a non-verbal learning disorder are
often present {3} [10, 26, 68].
Management: it is exceptional not to receive some
learning support or a special needs teacher for reading
comprehension and mathematics [29, 46]. Key ages for
assessment are around transitional stages in the chil-
dren’s school career. In the UK this coincides with the
start of primary education at 5 years, prior to secondary
school at 11 years, and at 16 years, preparatory to
leaving school or considering tertiary education. A
staged approach, assessed by classroom teachers in con-
cert with special educational needs co-ordinators have
an important role in highlighting needs. They, in turn,
are best served by informed educational psychologists,
supported by clinical psychologists knowledgeable about
the learning profile of these children. Some individuals
may show a decline in cognitive abilities [13]. The need
for formal educational assessment therefore depends on
perceived severity, and availability of resources {GP}.
Mental health
In common with other neurogenetic syndromes, emo-
tional and behavioural issues and psychiatric disorders
occur more frequently than in the general childhood
population, affecting 20–50 % of 22q11DS individuals
at any age. Often co-occurring, problems can include
attention deficit hyperactivity disorder (ADHD), obses-
sive compulsive disorder, depression, anxiety disorders
and autistic spectrum disorder (ASD) {2+} [1, 18] to
{3} [63]. Children often show rapid mood changes and
atypical social interaction skills, which may benefit from
assessment and intervention even if formal criteria for a
psychiatric diagnosis are not met {3} [53].
During adolescence and adulthood, risk of signifi-
cant and persistent mental health difficulties is in-
creased relative to comparable populations with mild
to moderate intellectual disability, and mood disorders
become increasingly common {3} [2, 17]. The preva-
lence of schizophrenia was 24 % in one adult study
{3} [45], and 22.5 % in another [15]. In addition,
many adults with 22q11DS suffer from depression or
generalised anxiety disorder [15]. Links between child-
hood adjustment and later psychiatric illness in
22q11DS remain uncertain, with no single symptom
or diagnosis (e.g., ADHD, ASD) strongly predicting
vulnerability to schizophrenia [1, 62]. Deterioration in
cognitive function, in mood and social interaction, or
worsening psychotic symptoms, are all potential indi-
cators of risk warranting early psychiatric assessment
(Table 2) [17, 25].
Many young adults experience social isolation and em-
ployment difficulties and continue to be prone to the emer-
gence of 22q11DS-related conditions.
Management: At all ages ready access to a psychologist or
psychiatrist is advantageous {GP}. The outcome of the
assessment determines the intervention (Table 3). When
someone is diagnosed with a psychiatric disorder,
Table 2 Therapeutic, psychological, behavioural and educational assess-
ments for early intervention {D}
• Early recognition of speech difficulties and speech therapy
intervention may reduce the emergence of deviant articulation.
Syndrome-specific leaflets are available [21].
• Adenoidectomy may worsen articulation and should only be
contemplated after expert speech assessment.
• Prompt referral for developmental monitoring involving assessment
for physiotherapy, and occupational therapy according to need.
• An eye test for squints and refractive errors at 3 years.
• Child and adolescent psychological and mental health services referral
for assessment when ASD, ADHD, emotional and behavioural issues
in the preschool and school age child cause distress or disruption.
Early psychotic symptoms should be assessed.
• Not all children will require a full educational assessment. This
may be evident in the preschool period or not raise concern until
adolescence when abstract concepts are increasingly a part of the
curriculum.With parental approval, inform the school of the condition
and potential needs. Explanatory syndrome-specific leaflet suitable
for teachers can be useful [21].
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medication might be considered (exercising caution in
relation to medical co-morbidities). In case of behav-
ioural problems, a psychological intervention could be
beneficial.
Discussion
In drawing up guidelines, it was deemed appropriate to
apply nationally accepted levels of clinical risk which
are evidence based. These can be adapted to suit local
circumstances and legal jurisdictions, for example
where defensive medicine plays a significant role in
clinical practice [5]. Examples of such controversy be-
tween specialists in different countries include cervical
X-rays for instability [5, 30, 48], and the practice of
palpation or MRI for presurgical location of carotid
artery anatomy [37, 57]. In the UK, consensus against
routine cervical X-rays has been agreed, but each sur-
gical unit continues their own individual policy on
obtaining a presurgical MRI to exclude medial displace-
ment of the carotid arteries. It is impractical to be
prescriptive in guidelines for management where con-
sensus may be lacking, such as encouraging use of a
signing system in early communication [41, 54] in the
context of characteristic speech and language delays;
some anecdotally see this as a distraction from focusing
on oral communication [20].
Child advocacy is valuable in promoting understand-
ing of the changing educational profile from among the
15 million children in the EU with special educational
needs [49, 64]. In Europe, each country’s special needs
education is defined and managed separately [38] and
parental preference may not be taken into account [49,
64], though all countries share the common goal of an
inclusive system which integrates those with disabilities
and vulnerabilities into main stream schooling as far as
possible. Some jurisdictions have an appeals system
should the educational authorities fail to initiate the
process or provide appropriate resources. In the UK,
this is the First-tier Tribunal [24]. Although the Euro-
pean Convention on Human Rights Article 1 Protocol 2
enshrines the right of all children to a suitable education it
does not guarantee it be of a suitable quality; this remains
dependent on each country’s priorities and resources.
The 22q11DS UK Guidelines group, by setting what it
perceives asminimum recommendations and not optimal ones
as advocated in other recent guidelines [5], aims to emphasise
the conserving of resources. They chime with the WHO
observation of the wide variation in European countries’ re-
sponse to the economic downturn, and its appeals to ‘viewing
fiscal balance as a constraint to be respected…towards an
emphasis on maximising the health system’s performance’
[38, 66]. The European Commission elaborates further on
health services sustainability, citing the need for reforms in
health budgets [14, 42]. The inception of minimum guidelines
should not imply rationing of core services to this group of
patients, whose needs must be balanced against possible ‘false
savings’ leading to increased costs in the long term.
Advocacy (Table 4) is highlighted as a driver for adherence
to the guidelines throughout the life cycle. Families with an
adult 22q11DS parent are particularly vulnerable. A member
of the multidisciplinary team, familiar with the condition,
often Paediatrician, Clinical Geneticist, less commonly Psy-
chiatrist or Psychologist, may be identified as ‘key worker’ in
liaising with the various health, education and social services
agencies. Developing a structure for transition from paediatric
to adult care for individuals with learning disability and
multiple comorbidities is a work in progress. The often
fragmented services for adolescents and young adults
with 22q11DS need to be brought together, using a
model such as The Netherlands transmural care
[60].The persistence of comorbidities and emergence of
new conditions in adulthood [3, 4, 7] require guidelines
which are continuous and flexible throughout life.
Table 3 Regular assessments for all individuals
• Annual
a. Full blood count for cytopaenias (of red cells, white cells and
platelets), serum calcium and thyroid function.
b. Height and weight.
c. Clinically monitor for autoimmune disease; perform autoantibody
testing as indicated.
d. Enquire about social–educational progress and psychological well-being.
• Regular dental care.
Table 4 Advocacy {GP}
• Social work and adult learning difficulty team referral where an
affected parent or the family are in need of support and advocacy.
• Coordinated care by a key worker. An informed primary care physician
or community paediatrician, and later the adult mental health team,
may be best placed to holistically guide the individual’s progress.
• Developing local expertise. The multisystem nature of 22q11DS has
led to a variety of specialities taking the lead in developing 22q11DS
services for their country and local geographical area. For instance,
psychiatry in Canada, Israel and Switzerland, cardiology in Italy and
Japan, genetics in Belgium, France and parts of the US, cleft surgery
centres in the US and UK.
• 22q11DS Personal Health Record booklet [44] is an example of a
patient held record of clinic attendances and list of prompts for
assessments to be performed.
• Managing Transitional Care from paediatric specialist to adult clinics.
Planning is required. Although congenital heart often has an established
pathway, holistic care for the young adult with 22q11DS has not. The
need for continued contact with health services and monitoring as for
younger individuals should be recognised and organised.
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Conclusions
A consensus comprehensive care plan is presented. An ac-
ceptable standard of care for individuals with 22q11DS re-
quires careful coordination and a multidisciplinary team ap-
proach, with access to services throughout the life cycle.
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